In vivo evaluation of 99mTc/188Re-labeled linear alpha-melanocyte stimulating hormone analogs for specific melanoma targeting.

Radiolabeled alpha-melanocyte stimulating hormone (alpha-MSH) analogs were examined in melanoma-bearing mice to determine the effects of peptide length, structure, and radiometal chelation chemistry on tumor targeting and in vivo biodistribution. The linear alpha-MSH analogs [Nle4,D-Phe7]alpha-MSH (NDPMSH) and [D-Phe7]alpha-MSH(5-10) (DPMSH) were radiolabeled with 99mTc and 188Re via the addition of tetrafluorophenyl mercapto-acetylglycylglycyl-gamma-aminobutyrate (MAG2) or tetrapeptide Ac-Cys-Gly-Cys-Gly (CGCG) chelation moieties. 125I-Tyr2-NDPMSH was obtained by direct iodination of the Tyr2 residue. Tumor uptake of 99mTc-labeled CGCG- and MAG2-NDPMSH analogs at 30 min postinjection were 6.52 +/- 1.11 %ID/g and 4.17 +/- 1.34 %ID/g, respectively, resulting in a significantly higher tumor-to-blood uptake ratio than that of 125I-NDPMSH or a shorter alpha-MSH analog, 99mTc-CGCG-DPMSH. The combination of radiolabeling efficacy and in vivo tumor uptake highlights the potential of 99mTc-CGCG-NDPMSH as a melanoma imaging agent.

[1]  S. Strand,et al.  Extracorporeal immunoadsorption compared to avidin chase: enhancement of tumor-to-normal tissue ratio for biotinylated rhenium-188-chimeric BR96. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[2]  M. Rajopadhye,et al.  Labeling cyclic glycoprotein IIb/IIIa receptor antagonists with 99mTc by the preformed chelate approach: effects of chelators on properties of [99mTc]chelator-peptide conjugates. , 1996, Bioconjugate chemistry.

[3]  D. Buchsbaum,et al.  A peptide‐based bifunctional chelating agent for 99mtc‐ and 186re‐labeling of monoclonal antibodies , 1994, Cancer.

[4]  V. Hruby,et al.  4-Norleucine, 7-D-phenylalanine-alpha-melanocyte-stimulating hormone: a highly potent alpha-melanotropin with ultralong biological activity. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[5]  V. Hruby,et al.  Potent and prolonged acting cyclic lactam analogues of alpha-melanotropin: design based on molecular dynamics. , 1989, Journal of medicinal chemistry.

[6]  W. Vale,et al.  Bombesin:potent effects on thermoregulation in the rat. , 1977, Science.

[7]  D. Wilbur,et al.  Specific and stable labeling of antibodies with technetium-99m with a diamide dithiolate chelating agent. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[8]  W. Gispen,et al.  Pharmacological evidence for the involvement of endogenous α-MSH-like peptides in peripheral nerve regeneration , 1995, Peptides.

[9]  T. Maughan,et al.  The use of a chelating derivative of alpha melanocyte stimulating hormone for the clinical imaging of malignant melanoma. , 1992, The British journal of radiology.

[10]  S. Strand,et al.  Extracorporeal whole-blood immunoadsorption enhances radioimmunotargeting of iodine-125-labeled BR96-biotin monoclonal antibody. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[11]  J. Fitzner,et al.  Development and biologic evaluation of a kit for preformed chelate technetium-99m radiolabeling of an antibody Fab fragment using a diamide dimercaptide chelating agent. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[12]  V. Hruby,et al.  Melanotropic peptide-conjugated beads for microscopic visualization and characterization of melanoma melanotropin receptors. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[13]  A. Eberle,et al.  [111In]‐DTPA‐labeled analogues of α‐melanocyte‐stimulating hormone for melanoma targeting: Receptor binding in vitro and in vivo , 1994, International journal of cancer.

[14]  K. Foon,et al.  Biodistribution, pharmacokinetic, and imaging studies with 186Re-labeled NR-LU-10 whole antibody in LS174T colonic tumor-bearing mice. , 1990, Cancer research.

[15]  V. Hruby,et al.  Cyclic melanotropins. 9. 7-D-Phenylalanine analogues of the active-site sequence. , 1985, Journal of medicinal chemistry.

[16]  Enhanced binding and inertness to dehalogenation of alpha-melanotropic peptides labeled using N-succinimidyl 3-iodobenzoate. , 1996 .

[17]  C. Pouton,et al.  Synthesis and biological evaluation of α-MSH analogues substituted with alanine , 1994, Peptides.

[18]  M. Mortrud,et al.  Cloning and Functional Characterization of a Family of Receptors for the Melanotropic Peptides , 1993, Annals of the New York Academy of Sciences.

[19]  A. Eberle,et al.  RADIORECEPTOR ASSAY FOR a-MSH USING MOUSE 816 MELANOMA CELLS+ , 1988 .

[20]  S. Vallabhajosula,et al.  Preclinical evaluation of technetium-99m-labeled somatostatin receptor-binding peptides. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[21]  S. Jurisson,et al.  Design and characterization of alpha-melanotropin peptide analogs cyclized through rhenium and technetium metal coordination. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[22]  G. Bormans,et al.  Complexes of technetium-99m with tetrapeptides, a new class of 99mTc-labelled agents. , 1995, Nuclear medicine and biology.

[23]  M. Zalutsky,et al.  Fluorine-18-labeled [Nle4,d-Phe7]-α-MSH, an α-melanocyte stimulating hormone analogue , 1997 .

[24]  C. G. Knight,et al.  A chelating derivative of alpha-melanocyte stimulating hormone as a potential imaging agent for malignant melanoma. , 1990, British Journal of Cancer.

[25]  J. Vanderheyden,et al.  Comparisons of the efficacy of 186Re- and 131I-labeled antibody in multicell spheroids. , 1992, International journal of radiation oncology, biology, physics.

[26]  S. Jurisson,et al.  Synthesis and characterization of rhenium-complexed alpha-melanotropin analogs. , 1997, Bioconjugate chemistry.

[27]  V. Hruby,et al.  Design, Synthesis, and Conformation of Superpotent and Prolonged Acting Melanotropins a , 1993, Annals of the New York Academy of Sciences.

[28]  G. Griffiths,et al.  Direct radiolabeling of monoclonal antibodies with generator-produced rhenium-188 for radioimmunotherapy: labeling and animal biodistribution studies. , 1991, Cancer research.

[29]  R. Cone,et al.  Cyclic lactam alpha-melanotropin analogues of Ac-Nle4-cyclo[Asp5, D-Phe7,Lys10] alpha-melanocyte-stimulating hormone-(4-10)-NH2 with bulky aromatic amino acids at position 7 show high antagonist potency and selectivity at specific melanocortin receptors. , 1995, Journal of medicinal chemistry.

[30]  V. Hruby,et al.  Biological and conformational examination of stereochemical modifications using the template melanotropin peptide, Ac-Nle-c[Asp-His-Phe-Arg-Trp-Ala-Lys]-NH2, on human melanocortin receptors. , 1997, Journal of medicinal chemistry.

[31]  A. Eberle,et al.  Characterization of Receptors for α-Melanocyte-stimulating Hormone on Human Melanoma Cells , 1989 .

[32]  L L Houston,et al.  Radiometal labeling of recombinant proteins by a genetically engineered minimal chelation site: technetium-99m coordination by single-chain Fv antibody fusion proteins through a C-terminal cysteinyl peptide. , 1995, Proceedings of the National Academy of Sciences of the United States of America.